Vivos Therapeutics: Sleep Center Strategy Gains Traction, But Cash Crunch Looms
The second quarter earnings call revealed a Vivos Therapeutics in motion. The acquisition of Sleep Centers of Nevada (SCN), now fully a year old, is delivering measurable results. Total revenue grew 35% quarter-over-quarter and 70% year-over-year, reaching $5.2 million, as the company's strategic pivot from a legacy VIP model to a vertically integrated sleep medicine platform begins to bear fruit. The call showcased a series of new recurring revenue initiatives, from remote patient monitoring (RPM) to an upcoming CPAP DME program, all riding on the strength of SCN's patient base.
The centerpiece is RPM. CEO Kirk Huntsman outlined the opportunity: “Based on the preliminary data currently available to us, we estimate an addressable population of approximately 16,000 existing CPAP patients from SCN's legacy CPAP patient population.” — R. Huntsman, Chairman and Chief Executive Officer · 2026-08-14 He added, “we estimate that approximately 5,000 to 7,500 of those patients could be candidates for enrollment over the next 6 to 12 months, subject to clinical appropriateness, patient consent, coverage and enrollment.” — R. Huntsman, Chairman and Chief Executive Officer · 2026-08-14 The projected revenue per patient per night of $40-50 points to a meaningful recurring stream, though adoption hinges on execution. A related CPAP DME program is slated for a phased launch in early Q4, with a potential contribution margin of $150k-$250k per month.
Beyond these new services, the synergy between SCN's diagnostics and the SAMC treatment centers is materializing. Referral volumes have surged: “Just since the end of the second quarter, we have been seeing 3 to 4x as many patients being referred by SCN physicians and nurse practitioners over to SAMC for treatment.” — R. Huntsman, Chairman and Chief Executive Officer · 2026-08-14 This directly fuels service revenue, which jumped $1.9 million in Q2. The company also highlighted the newly expanded Henderson facility, doubling production capacity, and advanced talks with cardiology groups in Florida and Arizona, each expected to require $800k-$1M capex and contribute revenue in Q1-Q2 2027.
Financially, the numbers show improvement but remain pressured. Gross margin expanded to 57% from 50% a year ago, driven by higher-margin service revenue. Yet the company still reported a net loss of $5.5 million for the quarter, and accumulated deficit stood at $138 million. Q2 revenue of $5.2 million was up 70% year-over-year, but operating cash burn continued at $9.2 million for the half. Management explicitly acknowledged going concern doubts, noting cash of just $1.8 million and a Nasdaq stockholder equity deficiency.
The operating model, however, is proving resilient. As the CEO stated on the prior call, “Our new model is highly dependent upon total doctor days.” — R. Huntsman, Chairman and Chief Executive Officer · 2026-04-15 In Q2, doctor availability improved, and the company now expects to be cash flow positive by late 2026 or early 2027. The CEO also reiterated the margin ramp: “I would say it's more of a ramp than a step function.” — R. Huntsman, Chairman and Chief Executive Officer · 2026-05-21 This aligns with the steady improvement and reflects management's confidence in scaling the model.
Ultimately, Vivos is charting a unique path in a market dominated by AI and tech themes. Its treatment program—from diagnosis to therapy—is a company-specific moat, but also an isolated one. The company's fate hinges on executing these new recurring revenue streams while managing its precarious balance sheet. If the initiatives land, the upside is substantial; if not, the capital gap could prove fatal. Investors will be watching Q3 for signs of that positive cash flow turning from projection to reality.
The infrastructure that we are building here at Vivos is designed to reinforce the core business, not simply operate alongside of it.